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Background 
Polyfluoroalkyl phosphate ester surfactants (PAPs) are derived from 
fluorotelomer alcohols (FTOHs), and are used to make food paper and 
board oil and water repellent.  PAPs were in 2009-2011 present in 40-57% 
of Danish food paper and board, particularly for popcorn and fast-food, and 
migrate to foods such as popcorn and butter (Begley et al. 2005, 2008, Trier 
and Alsing, DFVA 2012).  PAPs have been measured in human serum1 and 
breast milk (Kuwabo et al., 2013) In rats 8:2 diPAP [(F(CF2)8(CH2CH2O)]2-
P(O)OH is uptaken orally (gavage: 50 mg/kg) with linear elimination kinetics 
(half-life: 1.7 d) and metabolise to FTOHs and perfluoroalkyl carboxylic acids 
(PFCAs).  This is of concern, since PFCAs are linked to adverse effects in 
humans (Andersen et al., 2008; Kennedy et al., 2004.; Lau et al., 2007.; 
Steenland et al., 2010). Some PFCAs, FTOHs, and PAPs are suspected 
endocrine disrupters, and PAPs affects testosterone synthesis in-vitro 
(Rosenmai et al., 2013).  It is therefore relevant to investigate if such FTOH 
derived PFAS, with diPAP being the example, are precursors and thus 
sources of PFCAs in humans. 
 
Results and Discussion  
Figure 1 shows that the 13C4 8:2 diPAP is uptaken by humans in 0.9-6% from 
food as in rats (D’eon et al., 2011), but that the serum concentrations 
decrease linearly with time in a log-log plot, which has not previously been 
observed. This rules out regular linear clearance kinetics of the type C=Ae-kt 
and suggests an empirical power-law C=At-k. Non-linear pharmacokinetics 
has previously been observed for drugs such as the anti-cancer paclitaxel 
(Tuszynski et al.,  2008), where the power-law signifies that two competing 
and saturable transport/metabolic mechanisms exist (Fig. 2).  
The expected metabolites 13C4 8:2 FTCA,  PFOA and 
13C PFNA were found, 
and their concentrations increased with time.  This confirms that PFCAs can 
stem from diPAP, and likely also other FTOH based PFAS. 8:2 monoPAP 
was not found, similarly to what has been found in rats (D’eon et al., 2011). 
The MS Scan method allowed us to  search for non-target metabolites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Log-Log time-series of concentration C versus time t on a scale. The data suggests a 
power-law type of behavior C=A t –k with fitting constants A and k. 
 
Conclusions 
The data confirms that up to 7% (preliminary result) of 8:2 diPAP is uptaken 
by humans with food, and metaboilises to PFCAs, which confirms that FTOH 
based PFAS are sources of human PFCA exposure.  The elimination kinetics 
is non-linear, and consequently the half-life is not constant and increases 
with a decreasing blood concentration. Half-lives of other PFAS determined 
in highly exposed humans might therefore be underestimated. The study 
suggests that diPAP might distribute to another compartment than serum. 
Materials & Methods 
The study  included only healthy males (21-50 years), who were given one dose of 700 µg 13C4-8:2 diPAP (prepared as 0.7 mg/mL in 96% ethanol) spiked to a breakfast meal and left to absorb for 1 hr. Clean food was since provided for two weeks, 
and instructions were given on how to otherwise minimize PFAS exposure.  The study received ethical approval by the Danish Ethics Committee, since the 8:2 diPAP dose corresponded to a daily intake of 67% of a provisional limit value of 90 
µg/kg food (using the 2008 EFSA TDI value of 1.5 µg PFOA/kg bw/day). over the two weeks . 20 mL of blood  (and urine) were collected from the volunteers on Day 0 (before eating the dose),l and on days 1-2-3-6-10-14-27.  Blood was 
immediately prepared as serum and frozen until analysis. Triplicate analyses were made on Day 0, Duplicate on Days 1,3,14,27 and Single on Days 2, 6,10.  An in-house method was developed and validated using 350 µL serum, ultrafiltration for 
30 min/15000 G/4°C, transferred  to a frozen aluminum block, and the liquid decanted from the fat pellet into 1.5 mL PP tubes. 2 ng/mL internal standard, then 1050 µL cold AcN were added, mixed, shaken for 10 min, centrifuged 20 min/15000 
G/4C. The supernatant was transferred to a 350 µL tip vial, and the sample was blown down with N2 to exactly 120 µL, and  80µL AcN was added (40% organic strength).  The sample was filtered through 0.2 µm PP filter vial and 50 µL was 
injected onto the online-SPE-ESI–-QTOF-MS  (Agilent  1260-1290-6550), using C18 columns for SPE (3.0 mm id *1.7µm*20 mm) and for the analytical column (Acquity CSH 2.1 mm id *1.7µm*100 mm) and 10 mm guard column.  Analytical 
column eluents were water/AcN  (A1: 95%/5%, B1: 5%/95%), buffer: formic acid/ammonia (pH 9) and 2 mM ammonia fluoride. Online SPE eluents were A: 100% water (same strength of additives as above) and B1. The PFAS were analysed using 
an in-house validated MS-Scan method, with acceptance criteria of 5-10 ppm accuracy. Calibration curves were made in Bovine serum treated as the samples at levels 0.125 – 0.25 – 0.5 – 1 – 1.5 – 2.5 – 5 – 10 ng/mL  LODs of 26 PFAS ranged 
from  0.02 ng/mL to 0.5 ng/mL (8:2 diPAP: 0.08 ng/mL), and RSDs were  2.3 – 7%. 
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Fig. 2: Proposed kinetics and metabolic pathway for 8:2 diPAP in humans. Pipes symbolize linear 
kinetic pathways. Transport belts with limited speed symbolize saturable transport/metabolism. Note 
that two such saturable mechanisms compete for the same substrate (8:2 diPAP) in this model, as 
suggested by the apparent power-law behavior.  
Numerical fitting of the model shown in Fig. 2 shows that the elimination, i.e. 
the half-life of 8:2 diPAP is not constant. Initially, at high 8:2 diPAP serum 
concentrations, the half-life is short (0.9-1.4 days), and  similar to the half-life 
in rats. With decreasing serum concentrations, the elimination slows down, 
and half-lives become 6-11 times longer (5.7-15.4 days). If other PFAS 
behave similarly, the elimination of PFAS in averagely exposed humans 
might therefore be slower than estimated, based on half-lives determined 
from highly exposed humans. The identity of the second compartment 
remains unknown, but possibly PAPs containing a hydrophobic 
polyfluorinated part of diPAPs can distribute to both red blood cells and to 
fatty tissue as FTOH does (Bull et al., 2014).  
Aim 
The aim of the study was to assess 1) if  humans uptake an FTOH-derived 
diPAP with food, 2) to measure uptake profiles, 3) to obtain kinetic 
parameters by modeling the experiment 4) if diPAPs metabolise and hence 
are sources of perfluorocarboxylic acids (PFCAs), in humans. 
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